EC approves Perjeta for breast cancer

The European Commission approved an MAA from Roche (SIX:ROG; OTCQX:RHHBY) for Perjeta pertuzumab to treat previously untreated HER2-positive metastatic breast cancer. The product is approved in combination with Herceptin trastuzumab and docetaxel to treat adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti- HER2 therapy or chemotherapy. Perjeta is a mAb HER dimerization inhibitor that prevents HER2 from binding to other HER receptors ( HER1/EGF, HER3 and HER4). Roche's Genentech Inc. unit markets Herceptin in the U.S., while Roche markets it elsewhere. ...